

Molecular Mechanisms of Increased Nitric Oxide (NO) in Asthma: Evidence for Transcriptional and Post-Translational Regulation of NO Synthesis¹

Fuhua H. Guo,^{*†} Suzy A. A. Comhair,^{*†} Shuo Zheng,^{*†} Raed A. Dweik,^{*†} N. Tony Eissa,[‡] Mary Jane Thomassen,^{*} William Calhoun,[§] and Serpil C. Erzurum^{2*†}

Evidence supporting increased nitric oxide (NO) in asthma is substantial, although the cellular and molecular mechanisms leading to increased NO are not known. Here, we provide a clear picture of the events regulating NO synthesis in the human asthmatic airway in vivo. We show that human airway epithelium has abundant expression of NO synthase II (NOSII) due to continuous transcriptional activation of the gene in vivo. Individuals with asthma have higher than normal NO concentrations and increased NOSII mRNA and protein due to transcriptional regulation through activation of Stat1. NOSII mRNA expression decreases in asthmatics receiving inhaled corticosteroid, treatment effective in reducing inflammation in asthmatic airways. In addition to transcriptional mechanisms, post-translational events contribute to increased NO synthesis. Specifically, high output production of NO is fueled by a previously unsuspected increase in the NOS substrate, L-arginine, in airway epithelial cells of asthmatic individuals. Finally, nitration of proteins in airway epithelium provide evidence of functional consequences of increased NO. In conclusion, these studies define multiple mechanisms that function coordinately to support high level NO synthesis in the asthmatic airway. These findings represent a crucial cornerstone for future therapeutic strategies aimed at regulating NO synthesis in asthma. *The Journal of Immunology*, 2000, 164: 5970–5980.

Nitric oxide is increased in exhaled air of asthmatic individuals, and its levels return toward normal after treatment with corticosteroids (1–3). However, the factors regulating NO and its role in asthma are not known. Studies suggest that NO relaxes bronchial smooth muscles, inhibits inflammatory cell signaling proteins, or, conversely, contributes to airway inflammation and injury through the formation of toxic reactive nitrogen intermediates (RNI)³ (4–6). In general, the functional role of NO will depend on its concentration, site of production, and association with other molecules or proteins. The difficulty in elucidating the role(s) of NO in asthma stems from the multiple functions of NO, its production by different cell types, and its synthesis by multiple isoforms of NO synthase (NOS) (7). NO is endogenously synthesized by NOS (EC 1.14.13.39) (7). These enzymes convert L-arginine to NO and L-citrulline in a reaction that requires oxygen and NADPH (7). NOSI and -III, originally identified in neuronal and endothelial cells, respectively, depend on increases in calcium to bind calmodulin, which result in enzyme

activation and picomolar levels of NO production (7). NOSII is inducible in diverse cell types by cytokines and contains calmodulin as a subunit, allowing the production of nanomolar levels of NO at resting levels of intracellular calcium (7). Immunostaining of human bronchial biopsies suggest that increased NO in asthma may be related to NOSII expression (8, 9). However, NO biosynthesis is complex with multiple checkpoints, which include transcriptional, translational, and post-translational regulatory mechanisms (7). Studies elucidating the mechanisms of increased NO in asthma are essential for understanding the role of NO in asthma and are prerequisite for the design of future therapy targeting NO. In this context, the current studies are aimed at defining the cellular and molecular mechanisms leading to increased NO in asthmatic individuals.

Materials and Methods

Study population

Healthy, nonsmoking control individuals ($n = 23$) and asthmatic, nonsmoking individuals ($n = 28$) were studied. To be enrolled, asthmatic individuals must have shown a $\geq 14\%$ increase in absolute forced expiratory volume in 1 s (FEV_1), either spontaneously or after bronchodilator within the year before enrollment, and have satisfied the definition of asthma (10). Asthma severity and temporal course in volunteers included mild intermittent and mild persistent asthma (10). Asthmatic individuals had not received oral or i.v. corticosteroids within the previous 6 mo. All asthmatic individuals used short-acting inhaled β_2 -agonists on an as-needed basis, but did not use β_2 -agonist medication on the day of bronchoscopic study. Seven asthmatic individuals were studied while using inhaled corticosteroid (1000 $\mu\text{g}/\text{day}$ flunisolide for at least 3 wk). Healthy control volunteers were taking no medication. Exclusion criteria for both asthmatic and healthy control individuals included age over 65 yr or under 18 yr, pregnancy, HIV infection, history of respiratory infection in the previous 6 wk, tobacco use within the past 5 yr, and/or >10 pack yr of smoking. Additional exclusion criteria for control individuals included history of allergies, history of rhinitis and/or sinusitis, prolonged exposure to secondhand smoke at home or work, exposure to dusty environments or known pulmonary disease-producing agents, history of lung disease, or history of recurrent episodes of breathlessness, chest tightness, cough,

*Departments of Pulmonary and Critical Care Medicine, [†]Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195; [‡]Department of Medicine, Baylor College of Medicine, Houston, TX 77030; and [§]University of Pittsburgh, Pittsburgh, PA 15261

Received for publication November 24, 1999. Accepted for publication March 22, 2000.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by National Institutes of Health Grant HL03117.

² Address correspondence and reprint requests to Dr. Serpil C. Erzurum, Cleveland Clinic Foundation, 9500 Euclid Avenue/A90, Cleveland, OH 44195. E-mail address: erzurus@ccf.org

³ Abbreviations used in this paper: RNI, reactive nitrogen intermediates; NOS, NO synthase; FEV_1 , forced expiratory volume in 1 s; FVC, forced vital capacity; BAL, bronchoalveolar lavage; WCE, whole cell extract; GAS, IFN- γ activation site; IRF-1, IFN regulatory factor-1; SBE, Stat binding element; OPA, *o*-phthalaldehyde; ROS, reactive oxygen species; JAK, Janus kinase.

and/or sputum production. Control volunteers were also excluded from participating if physical examination demonstrated signs of wheezing on forced expiration. Pulmonary function testing for control and asthmatic individuals was performed on a spirometer (Spinnaker TL, Cybermedic, Louisville, CO). The forced vital capacity (FVC), FEV₁, and ratio of FEV₁ to FVC (FEV₁/FVC) were collected for each of three efforts. The study was approved by the Cleveland Clinic Foundation institutional review board, and written informed consent was obtained from all individuals.

Bronchoscopic studies

Airway epithelial cells were obtained by bronchoscopic brushing of second- and third-order bronchi through a flexible fiberoptic bronchoscopy as previously described (11). Because many of the studies described required large numbers of cells, not all studies could be performed on all samples. The number of samples evaluated for each experiment is stated in the text. Bronchoalveolar lavage (BAL) was also performed to recover epithelial lining fluid and inflammatory cells, i.e., alveolar macrophages (12). Briefly, three 50-ml aliquots of warm (37°C) sterile saline solution were infused into a segmental or subsegmental bronchus and then aspirated back. NO levels in bronchiolar gases were also measured during bronchoscopy as previously described (13). The bronchoscope was advanced into the lung, and real-time NO measurements were obtained at a rate of 20 samplings/s using a Teflon tube inserted through the working channel of the bronchoscope and connected to a chemiluminescence analyzer for detection of NO (NOA 280, Sievers, Boulder, CO) while the subject was holding his breath (13).

Cytokine levels in the lung were evaluated using a segmental bronchoprovocation with Ag in atopic asthmatics and nonatopic healthy controls (14). Ags for bronchial challenge (ragweed, grass, cat, or *Dermatophagoides farinae*) had no detectable endotoxin (<0.006 ng/ml; *Limulus* Lytase, BioWhittaker, Walkersville, MD). Ag sensitivity was determined by skin testing as previously described (14). Ag equal to the dose producing a 20% decrease in FEV₁ with whole lung Ag challenge was inserted into the right middle lobe subsegment during bronchoscopy. BAL (two 60-ml aliquots of warm sterile saline) was initially performed at baseline in the lingula and after Ag treatment at 8, 24, and 48 h in the right middle lobe. A quantitative ELISA for IFN- γ detection was purchased from Endogen (Cambridge, MA).

Cell culture

Airway epithelial cells obtained by bronchial brushing were cultured in serum-free Lechner and LaVeck medium (LHC-8, Biofluids, Rockville, MD) on plates pretreated with coating medium containing 29 μ g/ml collagen (vitrogen from Collagen Corp., Palo Alto, CA), 10 μ g/ml BSA (Biofluids), and 10 μ g/ml fibronectin (Calbiochem, La Jolla, CA) (12, 15). BET1A, a human bronchial epithelial cell line transformed with the T-Ag-containing plasmid pRSV-T (a gift from C. Harris, National Cancer Institute, Bethesda, MD) (16), was cultured in serum-free Lechner and LaVeck medium with additives 0.33 nM retinoic acid and 2.75 μ M epinephrine on plates precoated with coating medium as described above. A549 cells, an epithelial cell line derived from lung adenocarcinoma (American Type Culture Collection, Manassas, VA), were cultured in MEM (Life Technologies, Grand Island, NY) with 10% heat-inactivated FBS (15). The mouse macrophage cell line RAW264.7 was cultured in DMEM (Life Technologies) with 5% heated-inactivated FBS. Recombinant human IL-1 β and TNF- α were obtained from Genzyme (Cambridge, MA).

RNA extraction and Northern analysis

Total RNA was extracted and evaluated by Northern analyses as previously described or by slot-blot technique by application in duplicate of 0.5 μ g of total RNA to nylon membrane (Duralon, Stratagene, La Jolla, CA) (11). The membranes were hybridized with a ³²P-labeled 1.9-kb NOSII cDNA (pCCF21) (12) or, as a control, with γ -actin cDNA (pHF γ A-1) (17). Quantitation of NOSII mRNA relative to γ -actin was accomplished using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

NOSII mRNA transcription in airway epithelial cells

The NOSII gene transcription rate was measured by nuclear transcription run-on analyses (18). Nuclei were isolated from human airway epithelial cells freshly obtained or cultured for 8 h in LHC-8. Nuclei were incubated with α -³²P-labeled UTP (Amersham, Arlington Heights, IL; 40 μ Ci/ μ l) and ATP, CTP, GTP, and RNase inhibitor (Roche, Indianapolis, IN) to label nascent RNA transcripts. The ³²P-labeled RNA was purified on an RNase-free Sephadex G-50 quick spin column (Roche). Quantitation of labeled nascent RNA was accomplished by application of DNA targets to nylon membrane (Duralon, Stratagene) using a slot-blot technique and hybridization with ³²P-labeled RNA. The membranes were washed with

buffer containing RNase A (5 μ g/ml), RNase T1 (5 U/ml), and proteinase K (50 μ g/ml), respectively. The DNA targets included plasmids containing NOSII cDNA (pCCF21), a human γ -actin cDNA (17), or, as a negative control, the plasmid pSK Bluescript (Stratagene) containing no human DNA. The relative NOSII gene transcription rate in freshly obtained or cultured human airway epithelial cells was quantitated relative to γ -actin using a PhosphorImager (Molecular Dynamics).

RT-PCR and segmental analysis of the NOSII gene

cDNA was reverse transcribed from total RNA extracted from freshly obtained airway epithelial cells using Moloney murine leukemia virus RNase H⁻ reverse transcriptase, oligo(dT)₁₂₋₁₈ primer, and random hexamers (Life Technologies). cDNA was amplified by PCR using human NOSII-specific primers as previously described (19) for segmental analysis of the NOSII gene. PCR products were separated by gel electrophoresis and evaluated by Southern analyses using ³²P-labeled full-length human NOSII cDNA (19).

Electrophoretic mobility shift assays (EMSA)

Whole cell extract (WCE) from freshly obtained airway epithelial cells and untreated or cytokine-treated cell lines was prepared as previously described (15). The protein concentration was measured by the Coomassie protein assay (Pierce, Rockford, IL). The following oligonucleotides were used in this study: the IFN- γ activation site oligonucleotide (GAS) (5'-GCCTGATTTCCCGGAAATGACGGC-3') corresponding to human IFN regulatory factor-1 (IRF-1) promoter from -130 to -106 bp relative to the transcription start point (20), Stat binding element (SBE; 5'-GCTCTCTCCAGGAAGCAATG-3') corresponding to secreted type IL-1R antagonist gene promoter from bp -254 to -231 relative to the transcription starting point (21), and κ B site (5'-AACTCCGGGAATTTCCCTGGCCC-3') corresponding to human GRO α gene promoter from bp -82 to -60 relative to the transcription start point (22). Underlined sequences represent the consensus elements for GAS, SBE, and κ B, respectively. These oligonucleotides were synthesized by Operon (Alameda, CA) and end labeled with [γ -³²P]ATP by polynucleotide kinase.

Detection of IRF-1 GAS-Stat1, and SBE-Stat6 binding complexes was performed as previously described (20, 21). For NF κ B activation detection, ³²P-labeled oligonucleotide (0.2 ng) was incubated with 5 μ g of WCE protein in a 25- μ l final reaction volume containing 20 mM HEPES (pH 7.9), 5% glycerol, 50 mM NaCl, 1 mM DTT, 0.1 mM EDTA, 200 μ g/ml BSA, and 4 μ g of polydeoxyinosinic:polydeoxycytidylic acid (Amersham). The binding reaction mixture was incubated at room temperature for 15 min before electrophoresis on 4% acrylamide gels in 0.25 \times TBE (22.3 mM Tris, 22.2 mM borate, and 0.5 mM EDTA). The gels were dried and analyzed by autoradiography. To demonstrate specificity of binding, competition was performed by adding unlabeled oligonucleotide at a 100-fold molar excess of ³²P-labeled oligonucleotide probe in the binding reaction. To specifically identify DNA binding proteins, 2 μ g of rabbit anti-p50 (NF- κ B), p65 (RelA) polyclonal Abs (Santa Cruz Biotechnology, Santa Cruz, CA), Stat1 monoclonal or polyclonal Abs (20, 21), or rabbit anti-Stat6 (Santa Cruz Biotechnology) were added to the binding reaction mix and incubated for 20 min at 4°C before adding the ³²P-labeled oligonucleotide.

Western analyses

Airway epithelial cells freshly obtained by bronchoscopic brushing from asthmatics and healthy controls were suspended in buffer (3 mM DTT, 5 μ g/ml aprotinin, 1 μ g/ml leupeptin and pepstatin A, 0.1 mM PMSF, 1% Nonidet P-40, and 40 mM HEPES, pH 7.5), and cell lysate was prepared by three cycles of freeze/thaw. Total protein was measured using the Coomassie protein assay (Pierce). Lysate from A549 cells stimulated with 100 U/ml IFN- γ , 10 ng/ml TNF- α , and 10 U/ml IL-1 β for 72 h was used as a positive control (12). Whole cell lysate protein was denatured and reduced by treatment with buffer containing 0.05 M Tris (pH 6.8), 1% SDS, 10% glycerol, 0.00125% bromophenol blue, and 0.5% 2-ME for 3 min at 95°C. Total protein (50 μ g/lane) was separated by electrophoresis on an 8% SDS-polyacrylamide gel and then electrophoretically transferred onto nitrocellulose (NitroBind EP4HY315F5, Micron Separations, Westboro, MA) for 2 h at 4°C. Membranes were incubated with 1% BSA in TBS (20 mM Tris-HCl (pH 7.0) and 137 mM NaCl) with 0.1% Tween for 1 h at room temperature to block nonspecific binding, then with the primary anti-nitrotyrosine polyclonal Ab (1/2500) overnight at 4°C. Following washing, a peroxidase-conjugated secondary anti-rabbit IgG (1/5000 in 1% BSA/TBS-0.1% Tween, NA934, Amersham) was incubated with the membrane for 1 h at room temperature followed by washes with TBS-0.1% Tween.

The enhanced chemiluminescent system (Amersham) was used for detection of signals. To confirm the specificity of nitrotyrosine Ab, free nitrotyrosine (3.75 mM; Sigma, St. Louis, MO) was added to block staining with anti-nitrotyrosine. As a control for protein loading, Western analyses for β -actin were performed using a primary monoclonal anti- β -actin Ab (clone AC-74 (A-5316), Sigma). Nitrotyrosine quantitation was accomplished by the ratio of relative densitometric units of the multiple bands positive for nitrotyrosine to the β -actin band on Western blots using a Sierra Scientific resolution CCD camera (Sunnyvale, CA) and National Institutes of Health Image 1.6.

Western analysis of cell lysate for NOSII was performed using a rabbit polyclonal primary Ab against the carboxyl terminus of NOSII protein (Merck, Rahway, NJ) and a peroxidase-linked species-specific donkey anti-rabbit secondary Ab (Amersham). Quantitation of the NOSII relative to β -actin was accomplished by the ratio of relative densitometric units of the single NOSII band to β -actin band on Western blots using a Sierra Scientific resolution CCD camera and National Institutes of Health Image 1.6. Similarly, NOSI and NOSIII were evaluated by Western analyses using a polyclonal (rabbit) epitope purified anti-NOSIII Ab (PA1-037, Affinity BioReagents, Golden, CO) directed against human NOSIII peptide (aa 1179–1194) at a dilution of 1/1000 and a polyclonal (rabbit) anti-NOSI Ab (PA3-032, Affinity BioReagents) directed against the calmodulin binding domain (aa 724–739) of rat NOSI at a dilution of 1/5000. NOS Abs were tested for cross-reactivity to 500 ng each of purified NOSI, NOSII, or NOSIII. In addition, NOSII Ab specificity was ascertained by blocking the Ab using NO54 (1 μ g/ml), a free synthetic peptide corresponding to the carboxyl terminus of human NOSII (YRASLEMSAL-COOH; Merck), as previously described (23).

Arginine and citrulline analyses by HPLC

Two separate chromatography programs were employed to detect arginine or citrulline, but the same columns and fluorescence detector were used in each (23, 24). HPLC/fluorescence detection analysis was conducted with a Perkin-Elmer LC240 fluorescence detector (Norwalk, CT) and a Beckman HPLC system (Palo Alto, CA) using an excitation wavelength of 340 nm and an emission wavelength of 455 nm for detection. Amino acids were purchased from Sigma. Amino acid standards or lysate were mixed with a 4-fold volume of methanol, placed on ice for 5–10 min, then centrifuged at 13,000 rpm for 2 min. The supernatant (20 μ l) was mixed with 80 μ l of *o*-phthalaldehyde (OPA) reagent, and 50 μ l was injected by an autosampler. Separation of amino acid derivatives was conducted on a Hypersil 5, C18 column (125 \times 4.0 mm; Phenomenex, Belmont, CA), using a security guard column (C18 ODS, Octadecyl); length, 4 mm; inside diameter, 3.0 mm; Phenomenex). OPA reagent (6 mM) was prepared fresh daily in 0.1 M sodium borate ($\text{Na}_2\text{B}_4\text{O}_7$, Sigma) in H_2O containing 1% 2-ME. Amino acids were separated using gradients formed from two degassed solvent mixtures consisting of solvent A and solvent B. For arginine detection, solvent A consisted of 5 mM ammonium acetate, pH 6.0, and methanol (4/1, v/v), and solvent B was 100% methanol. For citrulline, solvent A was comprised of 12.5 mM sodium phosphate, pH 7.0, with 0.35% tetrahydrofuran, 10.5% methanol, and 4.5% acetonitrile, and solvent B was 100% methanol. For arginine, a flow rate of 0.5 ml/min was used with a gradient consisting of a linear increase of solvent B from 0–50% over 13 min, followed by a linear increase to 100% over the next 2 min, then 100% B for 3 min followed by decrease to 0% over 1 min. Cell lysate (volume equivalent to total protein, 2 μ g) was injected on the column, and peaks were compared with authentic standards of arginine (20–80 pmol; correlation coefficient of standard curves, ≥ 0.97). For citrulline, a volume equivalent to total protein of 10 μ g was injected on the column, and peaks were compared with authentic standards of citrulline (0.31–10 pmol; correlation coefficient of standard curves, ≥ 0.97).

Statistical analyses

Continuous variables were summarized by group as sample size, mean, and SEM unless otherwise indicated. Statistical comparisons were performed using ANOVA, Student's *t* test, or Smith-Satterthwaite *t* test as appropriate.

Results

Clinical characteristics

Healthy control and asthmatic individuals were similar in terms of age, sex, and race (Table I). Healthy control volunteers had no evidence of airflow limitation and asthmatics had mild degrees of

Table I. Characteristics of study population^a

	Control	Asthma	
		–CS	+CS
Age (years)	30 \pm 3	31 \pm 2	30 \pm 2
Sex (male/female)	15/8	14/7	5/2
Race (Caucasion/African American/Asian)	18/4/1	16/5/0	5/2/0
FVC (% predicted)*	103 \pm 4	89 \pm 4	82 \pm 5
FEV ₁ (% predicted)*	99 \pm 4	80 \pm 3	64 \pm 4
FEV ₁ /FVC*	81 \pm 2	76 \pm 2	67 \pm 3

^a Values are means \pm SE; –CS, not on inhaled corticosteroids; +CS, on inhaled corticosteroids.

* *p* < 0.02; all other comparisons are not significant.

airflow limitation as determined by ratios of FEV₁ to FVC (Table I).

Increased NO in asthma

We have previously determined lung tissue levels of NO in healthy controls by measures of NO in subsegmental airway (bronchiolar) gases by bronchoscopy during a breath-hold maneuver, i.e., head-space gas (13). Headspace NO accurately reflects the concentration of NO in liquids/tissues, since at atmospheric pressures over 97% of NO is rapidly distributed from the liquid to the gaseous phase (13, 25). In this study NO was measured in bronchiolar gases in the lower airway during bronchoscopy, while the individuals were instructed to breath-hold. Bronchiolar gas NO is significantly higher in asthmatics compared with controls (NO (ppb): asthma, 24 \pm 2 (*n* = 6); control, 6.7 \pm 0.3 (*n* = 5); *p* < 0.01).

Increased reactive nitrogen species in asthma

Reaction of NO and superoxide is rapid and produces peroxynitrite (6, 26). Peroxynitrite or other RNI can lead to nitration of tyrosine, allowing nitrotyrosine to be used as a collective marker of reactions between NO and reactive oxygen species (ROS) (6, 26). We quantitated the extent of tyrosine nitration and evaluated the range of proteins nitrated by Western analyses using specific anti-nitrotyrosine Abs. Multiple bands representing nitrated proteins




FIGURE 1. Increased nitrotyrosine in asthmatic airway epithelial cells. Western analysis of nitrotyrosine in cell lysates (50 μ g total protein/lane) of human airway epithelial cells obtained by bronchial brushing of healthy controls (lanes 1 and 2), asthmatics not receiving corticosteroid (–CS; lane 3), and asthmatics before (lane 4) and following 3 wk of inhaled corticosteroid therapy (+CS; lane 5). A range of nitrated proteins is seen, with increased nitration in asthmatic epithelial cell lysates. Western analysis using anti-human β -actin is shown as a control (lanes 6–10).




FIGURE 2. A, NOSI Ab detects purified NOSI at 0.5 ng and has no cross-reactivity to NOSIII (lane 5), but cross-reacts with NOSII (lane 4). NOSI is not detectable in airway epithelial cell lysates (HAEC; 50 μ g of total protein/lane; lanes 6 and 7). NOSII Ab is specific and sensitive with detection of human recombinant NOSII, no cross-reactivity to NOS III (lane 9) or NOSI (lane 10), and clear detection of NOSII in A549 stimulated with IFN- γ , TNF- α , and IL-1 β (CK; lane 13), but not in nonstimulated A549 (NS; lane 14). NOSII is easily detected in human airway epithelial cell lysates (HAEC; 50 μ g/lane; lanes 11 and 12). NOSIII Ab is sensitive and specific with detection of 0.5 ng of purified NOSIII, no cross-reactivity to NOSI (lane 18) or NOSII (lane 19), and clear detection of NOSIII in HUVEC in culture (lane 22). NOSIII is not detectable in human airway epithelial cell lysates (HAEC; 50 μ g/lane; lanes 20 and 21). B, Increased NOSII expression in asthmatic airway epithelial cells in vivo. Western analysis of NOSII in lysates of airway epithelial cells (50 μ g of total protein/lane) obtained by bronchial brushing of a healthy control (lane 1) or an asthmatic (lane 2) or from lysate of the human lung epithelial cell line A549 stimulated with IFN- γ , TNF- α , and IL-1 β (lane 3) or in nonstimulated A549 as a negative control (lane 4). The specificity of anti-NOSII Ab is confirmed by lack of cross-reactivity to purified bovine NOSIII (500 ng; lane 5), recombinant purified murine NOSII (500 ng; lane 6). Western analysis using anti-human β -actin is shown as a control (lanes 7–12). C, Western analyses of NOSI and NOSIII in human airway epithelial cells (HAEC; 30 μ g of total protein/lane; lanes 2, 3, 7, 8, 11, and 12) and alveolar macrophages (AM; 120 μ g of total protein/lane; lanes 4, 5, 9, 10, 13, and 14) in healthy controls (C) and asthmatics (A). Higher amounts of alveolar macrophage total protein were loaded to detect potentially low levels of NOS. Healthy or asthmatic epithelial cells and macrophages do not express NOSI (lanes 2–5) or NOSIII (lanes 7–10), although the positive control for purified NOSI (50 ng of purified protein; lane 1) and NOSIII (50 ng purified protein; lane 2) are clearly present at the appropriate sizes. Notably, NOSI Ab is not as specific as Abs against NOSII or NOSIII and cross-reacts with NOSII on Western analyses (lane 2, positive band at size appropriate for NOSII). Analysis of β -actin (lanes 11–14) demonstrates good integrity of protein and equal loading between epithelial cell samples and between alveolar macrophage samples.

are detected on Western analyses, which are blocked by free nitrotyrosine. Increased nitrotyrosine is detected in asthmatic airway epithelial cells compared with controls (nitrotyrosine/ β -actin: asthma, 12 ± 1 ($n = 5$); controls, 5 ± 1 ($n = 6$); $p = 0.004$; Fig. 1). The most prominent band in both healthy control and asthmatic cell lysates is at 44 kDa and is increased in asthmatic epithelial cell lysates. Interestingly, nitrotyrosine is nearly undetectable in airway epithelial cells from asthmatics using inhaled corticosteroids (Fig. 1). These studies show that NO is increasingly consumed by biochemical reactions in the lungs of asthmatics. In the context of increased consumption, increased NO in bronchiolar gases strongly suggests that NO synthesis is increased in asthma.

NOSII protein expression

To investigate NO synthesis, NOS protein expression was evaluated by Western analysis of airway epithelial cell lysates using

specific anti-NOS Abs. NOSI and NOSIII are not detectable in airway epithelial cells by Western analyses (Figs. 2, A and C). However, a protein (131 kDa) in the asthmatic and control airway epithelial cell lysates is detected using anti-NOSII Ab, which is similar in size to NOSII detected in positive control lysate from A549 cells stimulated with IFN- γ (100 U/ml), TNF- α (10 ng/ml), and IL-1 β (10 U/ml) for 72 h. Asthmatic airway NOSII expression is significantly higher than control (NOSII/ β -actin: asthma, 0.60 ± 0.08 ($n = 6$); control, 0.33 ± 0.06 ($n = 5$); $p < 0.05$; Fig. 2B).

Arginine levels in airway epithelial cells

The availability of intracellular arginine may regulate NO synthesis (27–31). Quantitation of arginine by HPLC reveals that asthmatic airway epithelial cells contain over 3-fold higher levels of arginine than healthy controls (arginine (mean \pm SD): control, 22 ± 3 pmol/ μ g total protein ($n = 3$); asthma, 77 ± 16 ($n = 3$);




FIGURE 3. Increased arginine in asthmatic airway epithelial cells. Chromatograms of OPA-derived airway epithelial cell lysate from a healthy control individual (A), an asthmatic individual (B), or an amino acid standard solution (C) containing 32 pmol each of citrulline (Cit), *N*-hydroxyarginine (NHA), and arginine (Arg). Amino acids falling within peaks include glycine and histidine (a); taurine (b); alanine, tyrosine, and NHA (c); and arginine (d).

$p = 0.02$; Fig. 3). Arginine and citrulline in BAL fluid and citrulline in airway epithelial cell lysates are not detectable (<0.3 pmol). Thus, post-translational mechanisms that support high output NO synthesis are induced in asthma.




FIGURE 4. Evaluation of NOSII mRNA expression in human airway epithelial cells (HAEC) and alveolar macrophages (AM). Northern analysis using a 32 P-labeled NOSII cDNA of total RNA (2 μ g RNA/lane) from airway epithelial cells obtained by bronchial brushing from two healthy controls (lanes 1 and 5) and two asthmatics (lanes 3 and 7) or from alveolar macrophages obtained at the same time by BAL in healthy controls (lanes 2 and 6) and asthmatics (lanes 4 and 8). NOSII mRNA is present in asthmatic and control airway epithelial cells, but is not detectable in the paired alveolar macrophages (paired samples of epithelial cells and macrophages from individuals are enclosed by brackets). Human 32 P-labeled γ -actin cDNA hybridization is shown as a control (lanes 9–16).




FIGURE 5. Quantitation of NOSII mRNA expression in control or asthmatic airway epithelial cells in the absence and the presence of inhaled corticosteroid. A, Representative Northern analysis of NOSII expression in airway epithelial cells obtained from a healthy control (lane 1) and an asthmatic before corticosteroid (–CS; lane 2) and following 3 wk of inhaled corticosteroid (+CS; lane 3; 2 μ g of total RNA/lane). Human 32 P-labeled γ -actin cDNA hybridization is shown as a control (lanes 4–6). B, NOSII mRNA expression in epithelial cells was quantitated in duplicate by a slot-blot technique using a 32 P-labeled NOSII cDNA or as a control γ -actin cDNA. Each point represents NOSII mRNA relative to γ -actin mRNA in a single individual. Asthmatic individuals studied in pairwise fashion before and after inhaled corticosteroid are connected by lines. NOSII mRNA in airway epithelial cells from asthmatics (–CS) is significantly higher than that in cells from controls or asthmatics (+CS). Asthmatics (+CS) are not significantly different from controls.

Increased NOSII mRNA in asthma

To evaluate whether increased NOS II protein in asthma was related to increased NOSII mRNA expression, Northern analyses of total RNA from airway epithelial cells freshly obtained by bronchoscopic brushing and from alveolar macrophages obtained by BAL of asthmatics ($n = 7$) and controls ($n = 9$) were performed. NOSII mRNA is demonstrated in airway epithelial cells as a prominent signal at 4.5 kb using a 32 P-labeled NOSII cDNA (pCCF21), with higher levels of NOSII mRNA in asthmatics (NOSII/ γ -actin mRNA: asthma, 0.62 ± 0.09 ($n = 7$); control, 0.27 ± 0.08 ($n = 9$); $p < 0.01$; Fig. 4). In murine systems, macrophages are a major source of NO (32). In paired samples of airway epithelium from bronchial brushing and human lung macrophages from bronchoalveolar lavage simultaneously obtained at bronchoscopy, abundant levels of NOSII are present in airway epithelium, but NOSII is not detected in macrophages by Northern analyses (Fig. 4).

Corticosteroids decrease NOSII mRNA in asthma

Corticosteroids are able to inhibit the cytokine- and endotoxin-induced expression of NOSII in vitro (33–35). Interestingly, NOSII mRNA expression in asthmatics using inhaled corticosteroid is less than that in asthmatics not using inhaled corticosteroid and is similar to that in healthy control individuals in this study (NOSII/ γ -actin mRNA: asthma with corticosteroid, 0.26 ± 0.07 ; Fig. 5). Three asthmatics, evaluated in a pairwise fashion, have




FIGURE 6. Segmental analyses of NOSII mRNA in airway epithelial cells by RT-PCR. Total RNA extracted from healthy control (lane 1), asthmatic (-CS; lane 2), and asthmatic (+CS; lane 3) were reverse transcribed to cDNA and amplified by PCR using Pfu DNA polymerase and specific NOSII primers subtending exon 5 (A), exons 8 and 9 (B), exons 9–11 (C), and exons 15 and 16 (D). PCR products were separated by gel electrophoresis and evaluated by Southern blotting using a ^{32}P -labeled probe for full-length human NOSII cDNA (A–D). The expected sizes of amplification products of NOSII cDNA produced by constitutive or alternative splicing are indicated by filled and open arrows, respectively. Total RNA from individuals were also analyzed by Northern hybridization with ^{32}P -labeled NOSII cDNA (E) and, as a control, with ^{32}P -labeled γ -actin cDNA (F). Alternatively spliced mRNA represent a minority of transcripts in all samples. Similar results were obtained in three separate experiments.

decreased NOSII mRNA expression following 3 wk of inhaled corticosteroid use (Fig. 5). These results suggest that the decreased NO and nitrotyrosine in asthmatics using inhaled corticosteroids are due to decreased NOSII gene expression.

Alternative splicing of NOSII in airway epithelial cells

mRNA regulation may be modulated at many points, including transcription, processing, and stability. The human NOSII gene contains 26 exons encoding a peptide of 1153 aa (19, 36). Recently, four sites of alternative splicing of the NOSII mRNA have been identified that lead to deletion of exon 5, exons 8 and 9, exons 9–11, or exons 15 and 16 (19). In tissue culture cells, NOSII induction by cytokines and endotoxin results in an increase in alter-




FIGURE 7. Loss of NOSII expression in the asthmatic airway epithelial cells placed ex vivo. Airway epithelial cells obtained by bronchial brushing were divided into two equal aliquots. RNA was extracted immediately from half of the cells, the other half was placed in culture for 24 h followed by RNA extraction. NOSII expression detected by Northern analysis in freshly obtained asthmatic airway epithelial cells (0 h; lane 1) is lost following 24-h culture (24 h; lane 2). Loss of expression also occurred in healthy control airway epithelial cells in culture (0, lane 3; 24 h, lane 4). Human ^{32}P -labeled γ -actin cDNA hybridization is shown as a control (lanes 5–8).

natively spliced mRNA transcripts (19). Importantly, the regions encoded by exons 8 and 9 are highly conserved among NOSs and are critical for NOS dimerization and subsequent synthetic activity (36). We evaluated asthmatic and healthy control airway epithelium for alternative splicing of NOSII mRNA. Total RNA extracted from the asthmatic or control airway epithelial cells was transcribed to cDNA, and segmental analysis of the NOSII gene was performed by PCR using specific primers. Southern analysis of PCR products show that alternatively spliced NOSII mRNAs are present, but are a minority of the NOSII mRNA in asthmatic and control airway epithelial cells (Fig. 6). The majority of NOSII expressed in the airway is processed normally, resulting in full-length NOSII that is capable of NO synthesis.

Loss of NOSII expression in airway epithelial cells ex vivo

Airway epithelial cells in vitro require stimulation with microbial products or cytokines to induce expression of NOSII (15, 37–39). To investigate whether the high level of NOSII mRNA in asthmatic airway epithelial cells was dependent upon the airway milieu, airway epithelial cells from healthy or asthmatic individuals were studied ex vivo. Each sample of airway epithelial cells obtained by bronchial brushing was divided into two aliquots; one-half of the sample was extracted for RNA immediately (0 h), and the remaining one-half was placed in culture with specialized serum-free medium (LHC8) and extracted for RNA after 24 h. Similar to previous work (12), NOSII expression is lost in primary




FIGURE 8. Active NOSII transcription in human airway epithelial cells (HAEC) determined by nuclear run-on. Nuclei extracted from airway epithelial cells freshly obtained at bronchoscopy or after 8-h culture were analyzed for NOSII transcriptional rate. ^{32}P -labeled nascent nuclear RNA was hybridized to nylon membrane-bound DNA targets, including NOSII, γ -actin, and plasmid containing no human cDNA (pSK). Active NOSII gene transcription was detected in human airway epithelial cells in vivo, but the transcriptional rate decreased with culture ex vivo.




FIGURE 9. IFN- γ in BAL fluid from control ($n = 8$) and asthmatic ($n = 9$) individuals at baseline and following segmental bronchoprovocation with Ag. BAL was obtained at baseline in the lingula and after Ag challenge in the right middle lobe at 8, 24, and 48 h. IFN- γ detected in BAL by quantitative ELISA are not significantly different between controls and asthmatics at baseline ($p = 0.06$). However, with Ag challenge, asthmatic IFN- γ is significantly higher than the control value at all other time points.

airway epithelial cells of healthy controls in culture ($n = 4$ paired samples; Fig. 7). Despite the high levels of NOSII mRNA in the asthmatic airway epithelial cells, NOSII mRNA is not detectable by Northern analysis following 24-h culture ($n = 3$ paired samples). These data provide strong support that NOSII mRNA expression is dependent on factors and/or conditions related to the airway environment.

NOSII transcriptional rate in vivo

Evidence in the literature and our previous work point to transcriptional regulation of NOSII mRNA (15, 37–39). In this study the rate of NOSII transcription relative to γ -actin in vivo was compared with rates in vitro by run-on experiments using nuclei ex-




FIGURE 10. Inhibition of NOSII induction in airway epithelial cells in vitro by the TK inhibitor, genistein. NOSII mRNA is not detected by Northern analyses in airway epithelial cells in vitro (lane 5), but is induced in airway epithelial cells exposed to IFN- γ (100 U/ml) and IL-4 (10 ng/ml; lane 1). Conditioned medium (CM) was derived from the overlying tissue culture medium of airway epithelial cells treated with IFN- γ (100 U/ml) and IL-4 (10 ng/ml) for 1 h, followed by removal and discarding of the cytokine-containing medium, vigorous washing of cells, and culture in fresh medium for 23 h. Transferable, soluble mediators present in CM also induce NOSII mRNA (lane 3). Genistein inhibits NOSII induction by IFN- γ /IL-4 (lane 2) and CM (lane 4). Genistein alone has no effect on NOSII mRNA expression (not shown). Human 32 P-labeled γ -actin cDNA hybridization is shown as a control (lanes 6–10). Similar results were obtained in three separate experiments using airway epithelial cells from three healthy control individuals.

tracted from airway epithelial cells freshly obtained at bronchoscopy or after 8-h culture. Active transcription of NOSII mRNA is present in airway epithelial cells in vivo, but transcription of NOSII in airway epithelial cells ex vivo decreases relative to in vivo levels (NOSII mRNA transcription relative to γ -actin mRNA (mean \pm SD): freshly obtained human airway epithelial cells, $15 \pm 4\%$; airway epithelial cells after 8-h culture, $2 \pm 2\%$; $n = 2$ paired samples; Fig. 8). The rapid decrease in NOSII transcriptional rate ex vivo provides conclusive evidence that airway epithelial cells are dependent upon an in vivo factor(s) for expression and regulation of the NOSII gene.

IFN- γ in BAL fluid

IFN- γ is essential for NOSII expression in human primary airway epithelial cells in vitro (15). In this study asthmatics have a trend toward higher IFN- γ in BAL fluid compared with healthy controls ($p = 0.06$; Fig. 9). IFN- γ in BAL fluid of asthmatics is significantly higher than that in healthy controls using a segmental bronchoprovocation model to mimic asthma exacerbation (all time points, $p < 0.03$; Fig. 9). These results support that asthmatics have increased levels of IFN- γ , a cytokine crucial for NOSII gene expression (15, 37–39).

We have previously shown that IFN- γ and IL-4 induce expression of NOSII in airway epithelial cells in culture that is dependent upon new protein synthesis and epithelial cell production of soluble mediators (15). IFN- γ induces gene expression through the Janus kinase (JAK)-Stat1 pathway, which involves a tyrosine phosphorylation cascade (40, 41). In this context, pretreatment with genistein, a tyrosine kinase inhibitor, prevents IFN- γ /IL-4 induction of NOSII expression in airway epithelial cells (Fig. 10). Interestingly, genistein also prevents NOSII induction by the soluble mediators present in conditioned medium of airway epithelial cells exposed transiently to IFN- γ /IL-4 (Fig. 10). These data support an essential role of tyrosine phosphorylation signaling events in NOSII expression in human airway epithelial cells.

Activation of Stat in airway epithelial cells

To investigate the involvement of tyrosine kinase signaling and specifically JAK-Stat pathway activation in NOSII expression in asthma in vivo, EMSA of WCE from freshly obtained airway epithelial cells of asthmatics and controls was performed (Fig. 11). Several cytokines implicated in the airway inflammatory reaction of asthma activate the JAK-Stat1 pathway (40, 41). While IFN- γ uses Stat1, IL-4 activates Stat6 (40, 41). Binding complexes in airway epithelium are detected using the GAS element from the human IRF-1 promoter. Stat1 is confirmed in the complex by anti-human Stat1 Abs (Fig. 11A). Stat1 activation is increased in asthmatic airway epithelial cells compared with control (densitometric units of binding complex: asthma, 46 ± 2 ($n = 5$); control, 22.6 ± 0.6 ($n = 6$); $p < 0.01$). A low level of Stat6 activation is also noted (Fig. 11A). Using a Stat binding element (SBE) from the secreted-type IL-1R antagonist gene as a probe to specifically detect Stat6 activation, EMSA confirms a very low level of Stat6-containing complex in the cell lysates of the same individuals used for detecting Stat1 activation (data not shown). These data are compatible with our previous report that WCE from airway epithelial cells stimulated with IL-4 (10 ng/ml) in culture for 15 min induced a very faint binding complex containing Stat6 (15).

The signal transduction pathway through NF- κ B was also investigated by EMSA using NF- κ B binding element from the human GRO α gene (22) (Fig. 11B). Although cytokines that signal through NF- κ B may be increased in asthma, asthmatics in this study have low levels of NF- κ B activation in airway epithelial




FIGURE 11. EMSA of Stat1 and NF- κ B activation in airway epithelial cells in vivo. EMSA of DNA-protein complexes were resolved on nondenaturing 6% polyacrylamide gels, followed by autoradiography. *A*, Detection of Stat1 activation. EMSA of WCE (5 μ g protein/lane) of freshly obtained airway epithelial cells from a healthy control (*lanes 5–8*) or asthmatic individual (*lanes 9–13*) were performed using 32 P-labeled oligonucleotide containing the IRF-1 GAS element. As a positive control, EMSA with WCE from the transformed human airway epithelial cell line BET1A, not stimulated (NS, *lane 1*) or stimulated with IFN- γ (100 U/ml) for 30 min (*lanes 2–4*), were also performed. Unlabeled oligonucleotide IRF-1 GAS at 100-fold molar excess of 32 P-labeled oligonucleotide or anti-Stat1 polyclonal antibodies (pAb) or mAb were added to the binding reactions as indicated to verify Stat1 protein in binding complexes. The arrow designates a binding complex containing Stat1. Stat1 activation is noted in healthy controls, but is increased in asthmatic airway epithelium. Low level Stat6 activation is also noted (binding complex above Stat1, arrow) and is similar in asthmatics and controls. *B*, Detection of NF- κ B activation. EMSA of WCE (5 μ g protein/lane) of freshly obtained airway epithelial cells from a healthy control (*lanes 6–9*), or an asthmatic (*lanes 10–13*) were performed using 32 P-labeled oligonucleotide containing the [kappa]B element. The mouse macrophage cell line RAW264.7, not stimulated (NS, *lane 1*) or stimulated with LPS (*lanes 2–5*), were used as negative and positive controls for NF- κ B activation in EMSA. Unlabeled oligonucleotide [kappa]B at 100-fold molar excess of 32 P-labeled oligonucleotide^{XXV} or anti-P50 (NF- κ B) or P65 (RelA) polyclonal Abs (pAb) were added to the binding reactions as indicated to verify various RelA family binding complexes. Arrows designate binding complexes containing homodimers or heterodimers of the Rel family (C1, P50-containing complex; C2, P65- and P50-containing complex). NF- κ B activation is present at similar levels in healthy and asthmatic airway epithelial cells.

cells, similar to control values (densitometric units: asthma, 126 ± 4 , ($n = 5$); control, 127 ± 4 ($n = 6$); $p > 0.5$).

Discussion

These studies identify transcriptional and post-translational mechanisms regulating NO synthesis in the human airway and quantify NO consumption by oxidative reactions in airway epithelium in vivo. More than one-third of the NO synthesized in biologic systems may be consumed by chemical reactions (42). Since NO is freely diffusible, consumption of NO can occur at different sites within cells, extracellular fluids, or intravascular compartments of

the lung (43). The presence of NO reaction products, e.g., nitrite, nitrate, and *S*-nitrosothiol, in the lung epithelial lining fluid indicates that a significant proportion of the NO produced is consumed by chemical reactions in the lung (13, 44, 45). Abnormalities of NO reaction products are present in asthma, as evidenced by decreased *S*-nitrosothiol levels in tracheal aspirates from children with asthmatic respiratory failure (44). *S*-nitrosothiols may function as a reservoir, or storage pool, for enzymatically synthesized NO (44). In theory, accelerated degradation of *S*-nitrosothiols in the asthmatic airway may also contribute to increase NO in asthmatic lungs and exhaled air. In addition to reaction with thiols, NO

reacts with ROS to generate toxic RNI (6, 26). RNI modify tyrosine in proteins by a number of complex mechanisms to create nitrotyrosines, allowing nitrotyrosine to be used as a collective marker of NO-ROS consumptive processes (6, 26). In contrast to decreased *S*-nitrosothiols, increased nitrotyrosine in asthmatic airway epithelium has been inferred from immunostaining of lung biopsies (9). In this study we demonstrate increased nitrotyrosine in asthmatic airways compared with controls and show that a range of proteins is modified in the airway epithelium. Recent *in vitro* studies have identified specific proteins modified by nitration and, in some cases, functional consequences (6, 46). For example, free nitrotyrosine is incorporated into α -tubulin post-translationally in the lung epithelial cell line A549, which alters microtubule function, leading to changes in cell morphology and epithelial barrier function (46). Although the precise protein targets undergoing tyrosine nitration in the airway epithelial cells *in vivo* are not determined, these studies identify a specific pattern of nitrated proteins in airway epithelium that is increased in asthmatic airways.

The concentration of NO in any biologic system is a consequence of its rate of enzymatic formation and consumption/scavenging by other biomolecules. In the context of increased scavenging of NO by ROS, increased enzymatic synthesis is a likely mechanism for increased NO levels in asthma. However, NO biosynthesis is regulated at multiple levels in cells, i.e., NOS gene transcription, mRNA processing, protein expression and dimerization, and enzyme reaction kinetics (7). Immunostaining of lung tissue has suggested that NOS protein is increased in the airway epithelium of the asthmatic lung (8, 9). In this study NOSII protein is present in control airway epithelial cells, but is clearly increased in asthmatic airways *in vivo*. However, NO synthesis is dependent upon post-translational modifications to generate active NOS. Specifically, NOSs are synthesized as monomers and must dimerize to generate NO (7). Recently, deletion of regions critical for NOS dimerization due to alternative splicing of the NOSII mRNA has been identified (36). In tissue culture cells, NOSII induction by cytokines and endotoxin results in an increase in both constitutively and alternatively spliced mRNA transcripts (19, 36). In contrast, we show that the majority of NOSII mRNA in airway epithelial cells *in vivo* are processed as full-length transcripts.

Enzyme-catalyzed NO synthesis involves hydroxylation of arginine to generate *N*-hydroxyarginine, an enzyme-bound intermediate, which is then converted to citrulline. The intracellular concentration of arginine (several hundred micromolar concentrations) (27, 28, 30, 47) has been reported to far exceed the K_m of the NO synthases (5–10 μ M) (47). In this context, it would seem unlikely that arginine is ever rate limiting to the enzyme. However, arginine administration drives NO synthesis *in vivo* and in cell culture systems (27, 30, 31, 49). Independent of substrate effects, arginine may regulate enzyme reaction kinetics through effects on enzyme dimerization or influences on the reduction potential of the enzyme (7). In addition, sequestration of arginine to regions in the cell that are poorly accessible to NOS may account for situations in which increasing arginine drives enzyme activity, even when arginine is available in apparent excess (50). In support of these concepts, the kinetics of NO production by NOSII in activated macrophages over a range of arginine concentrations reveal a K_m for arginine in intact cells of 73–150 μ M (49, 51). Intracellular arginine can be increased by *de novo* synthesis through regeneration from citrulline or transport from extracellular sources (28–30, 47). Arginine synthetic pathways and transporter systems are induced coordinately with NOSII induction in cell cultures. Argininosuccinate synthetase, the rate-limiting enzyme in the synthesis of arginine, is induced by endotoxin and IFN- γ , suppressed by corticosteroids, and generally mirrors NOS induction in

smooth muscle cells *in vitro* (29). In this study arginine is present in healthy control airway epithelial cells (~110 μ M), while citrulline is not detectable. Importantly, arginine levels are increased >3-fold in asthmatic epithelial cells, suggesting coordinate induction of the arginine synthetic pathways and/or cationic amino acid transporters to support a high rate of NO synthesis in asthma.

Although translational and post-translational mechanisms are important in the regulation of NO synthesis, NOSII is substantially regulated at the level of transcription (37–39). As we and others have previously shown, healthy human airway epithelium *in vivo* expresses the NOSII gene continuously at abundant mRNA levels (12, 52). Here, we show that the NOSII gene is actively transcribed in airway epithelial cells *in vivo*. Transcription of the NOSII gene is at 15% the transcription rate of γ -actin, an abundantly expressed mRNA in the airway epithelium (11). NOSII mRNA expression in asthmatic airway epithelium is higher than that in controls *in vivo*, but is not increased in asthmatics receiving inhaled corticosteroid. Inhaled corticosteroids are the most effective therapies for reducing inflammation in asthma. While the use of inhaled corticosteroids as a first-line treatment in asthma has increased, little is known regarding the cellular and molecular mechanisms that contribute to the efficacy of inhaled corticosteroids *in vivo*. Several studies have shown that inhaled or *i.v.* corticosteroids reduce exhaled NO (1–3). *In situ* analysis of the asthmatic airway suggested that NOSII expression is reduced by corticosteroids (9). In general, mechanisms by which corticosteroids regulate NOSII gene expression *in vivo* are not known. *In vitro*, glucocorticoids inhibit NOSII expression at multiple levels, including inhibition of gene transcription, reduction of mRNA translation, and increased degradation of NOSII protein (33–35). Increased NOSII mRNA in asthma, which is down-regulated by corticosteroid, supports an association between NOSII expression and airway inflammation.

Loss of NOSII expression in control and asthmatic airway epithelial cells *ex vivo* substantiates a critical link between airway conditions and/or factors *in vivo* and NOSII expression. Induction of NOSII expression varies in different cell types, but typically is increased by cytokines (15, 32, 37–39). IFN- γ is crucial for induction of NOSII expression in airway epithelial cells *in vitro* (15). IFN- γ signaling to gene expression begins with a specific receptor interaction and oligomerization of receptor chains, causing a tyrosine kinase cascade. Stat1 phosphorylation, dimerization, and translocation to the nucleus are followed by binding to regulatory DNA elements to activate transcription of IFN-stimulated genes (40, 41). We and others have shown that IFN- γ leads to Stat1 activation in primary human airway epithelial cells in culture (15, 53). In this study we show that tyrosine kinase inhibitor abolishes induction of NOSII in airway epithelial cells. Recently, Stat1 activation has been demonstrated in the asthmatic airway by nuclear localization of Stat1 in airway epithelial cells and demonstration of phosphorylation of Stat1 by Western analyses of epithelial cell lysates (54). The Stat1 activation correlated with the induction of IFN- γ /Stat1-stimulated genes, including IRF-1, which has been identified as essential for NOSII activation in murine macrophages (32). In this study Stat1 activation quantitated by EMSA is present in controls, but is increased in asthmatic airway epithelial cell lysates. In contrast to increased Stat1 activation in the asthmatic airway, other cell-signaling proteins are not increasingly activated. We show that Stat6 and NF- κ B activation are not increased in asthmatic airway compared with those in healthy controls. Previous study has shown that Stat3 and AP-1 activation is not increased in asthma (54). Stat1 tyrosine phosphorylation and translocation to the nucleus occur in response to many growth factors and cytokines, including IFN- γ , IL-10, IFN- α/β , epidermal growth

factor, platelet-derived growth factor, GM-CSF, IL-6, IL-11, leukemia inhibitory factor, ciliary neurotropic factor, oncostatin M, growth hormone, prolactin, and CSF-1 (40, 41). IFN- γ has both anti- and proinflammatory effects in the lung. In fact, IFN- γ mediates numerous anti-inflammatory effects, including inhibition of Ag and Th2-cell induced pulmonary eosinophilia and airway hyper-reactivity (55). However, IFN- γ is also implicated in the pathobiology leading to airway inflammation and hyper-reactivity in asthma (55–58). For example, OVA-sensitized mice develop airway hyper-responsiveness dependent upon IFN- γ (57). Further, adoptive transfer of Th1 lymphocytes, which characteristically produce IFN- γ , increases airway inflammation in a murine model of allergic asthma (58). In this study IFN- γ levels are higher in asthmatic epithelial lining fluid than in controls following a segmental bronchoprovocation with Ag. The large number of IFN- γ /Stat1-stimulated genes, including IRF-1, ICAM-1, and NOSII, are probably involved in the airway inflammatory events of asthma. Collectively, these data provide strong support for Stat1 activation mediating NOSII gene expression in human airway epithelial cells *in vivo*.

NF- κ B activation and binding to κ B DNA elements in the 5'-flanking region of the NOSII gene play a role in the cytokine induction of NOSII in the human lung epithelial cell line A549 *in vitro* (37–39). However, studies of NF- κ B activation in asthma are conflicting, perhaps in part due to the types of samples analyzed (48, 54). Expecterated sputum from asthmatics or pooled biopsies of asthmatic airways have shown increased NF- κ B activation compared with controls (48), while no increase in activation was noted by nuclear localization of NF- κ B in biopsies and bronchial brushings of asthmatic airway epithelium (54). Here, NF- κ B activation in asthmatic airway epithelial cells obtained by bronchial brushing is at levels similar to those in healthy controls. Our results support that increased NF- κ B activation is not involved in NOSII induction in asthmatic airways. On the other hand, NF- κ B activation is present in control and asthmatic epithelia and may contribute to the tonic expression of NOSII in the airway.

In conclusion, multiple mechanisms function coordinately to support high level NO synthesis in the asthmatic airway. Human airway epithelium has abundant expression of NOSII due to continuous transcriptional activation of the gene *in vivo*. We propose that increased NOSII gene expression in asthmatic airways is related to increased Stat1 activation caused by increased cytokines, e.g., IFN- γ . High levels of intracellular arginine may enhance enzyme reaction kinetics and drive NO synthesis. Thus, airway epithelial cells have highly efficient NO synthetic machinery, which is amplified in airway inflammation. These studies lay the groundwork for evaluating therapeutic strategies to decrease NO and RNI formation through inhibitors of arginine transport systems, specific inhibitors of NOSII, or antioxidant augmentation.

Acknowledgments

We thank H. Abu-Soud for advice on HPLC; C. Harris for BET-1A; D. Mytych for IL-4; Genentech for human IFN- γ ; D. J. Stuehr for recombinant NOSIII and NOSII; J. L. Humes for anti-NOSII Ab; Affinity Bioreagents Laboratories for anti-NOSI and anti-NOSIII Abs; O. Utenthal for anti-nitrotyrosine Ab; L. Kedes for pHF γ A-1; J. Lang for artwork; J. Hammel for biostatistical testing; and F. T. Kaneko and M. Numata for technical support.

References

- Massaro, A. F., B. Gaston, D. Kita, C. Fanta, J. S. Stamler, and F. M. Drazen. 1995. Expired nitric oxide levels during treatment of acute asthma. *Am. J. Respir. Crit. Care. Med.* 152:800.
- Kharitonov, S. A., D. H. Yates, and P. J. Barnes. 1996. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. *Am. J. Respir. Crit. Care. Med.* 153:454.
- Silkoff, P. E. S., P. A. McClean, A. S. Slutsky, M. Caramori, K. R. Chapman, C. Gutierrez, and N. Zamel. 1998. Exhaled nitric oxide and bronchial reactivity during and after inhaled beclomethasone in mild asthma. *J. Asthma* 35:473.
- Sanders, S. P. 1999. Nitric oxide in asthma. *Am. J. Respir. Cell Mol. Biol.* 21:147.
- Raychaudhuri, B., R. Dweik, M. J. Connors, L. Buhrow, A. Malur, J. Drazba, A. C. Arroliga, S. C. Erzurum, M. S. Kavuru, M. J. Thomassen, et al. 1999. Nitric oxide blocks nuclear factor- κ B activation in alveolar macrophages. *Am. J. Respir. Cell Mol. Biol.* 21:311.
- van der Vliet, A., J. P. Elserich, M. K. Shigenaga, and C. E. Cross. 1999. Reactive nitrogen species and tyrosine nitration in the respiratory tract. *Am. J. Respir. Crit. Care. Med.* 160:1.
- Stuehr, D. J. 1999. Nitric oxide synthesis and breakdown. *Biochim. Biophys. Acta* 1411:217.
- Hamid, Q., D. R. Springall, V. Riveros-Moreno, P. Chanez, P. Howarth, A. Redington, J. Bousquet, P. Godard, S. Holgate, J. M. Polak, et al. 1993. Induction of nitric oxide synthase in asthma. *Lancet* 342:1510.
- Saleh, D., P. Ernst, S. Lim, P. J. Barnes, and A. Giaid. 1998. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. *FASEB J.* 12:929.
- National Asthma Education and Prevention Program. 1997. *Guidelines for the Diagnosis and the Management of Asthma, Expert Panel Report II*. National Asthma Education and Prevention Program, National Institutes of Health, Bethesda, Publication 97–4051.
- Erzurum, S. C., C. Danel, A. Gillissen, C.-S. Chu, B. C. Trapnell, and R. G. Crystal. 1993. *In vivo* antioxidant gene expression in human airway epithelium of normal individuals exposed to 100% O₂. *J. Appl. Physiol.* 75:1256.
- Guo, F. H., H. R. De Raeve, T. W. Rice, D. J. Stuehr, F. B. J. M. Thunnissen, and S. C. Erzurum. 1995. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium *in vivo*. *Proc. Natl. Acad. Sci. USA* 92:7809.
- Dweik, R. D., D. Laskowski, H. M. Abu-Soud, F. T. Kaneko, R. Hutte, D. J. Stuehr, and S. C. Erzurum. 1998. Nitric oxide synthesis in the lung. *J. Clin. Invest.* 101:660.
- Calhoun, W. J., E. C. Dick, L. B. Schwartz, and W. W. Busse. 1994. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. *J. Clin. Invest.* 94:2200.
- Guo, F. H., K. Uetani, S. J. Haque, B. R. G. Williams, R. A. Dweik, F. B. J. M. Thunnissen, W. Calhoun, and S. C. Erzurum. 1997. Interferon γ and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. *J. Clin. Invest.* 100:829.
- Reddel, R. R., Y. Ke, B. I. Gerwin, M. G. McMenamin, J. F. Lechner, R. T. Su, D. E. Brash, J. B. Park, J. S. Rhim, C. C. Harris, et al. 1988. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. *Cancer Res.* 48:1904.
- Gunning, P., P. Ponte, H. Okayama, J. Engel, H. Blau, et al. 1983. Isolation and characterization of full-length cDNA clones for human α -, β -, and γ -actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed. *Mol. Cell. Biol.* 3:787.
- Nakamura, H., K. Yoshimura, H. A. Jaffe, and R. G. Crystal. 1991. Interleukin-8 gene expression in human bronchial epithelial cells. *J. Biol. Chem.* 266:19611.
- Eissa, N. T., A. J. Strauss, C. M. Haggerty, E. K. Choo, S. C. Chu, and J. Moss. 1996. Alternative splicing of human inducible nitric-oxide synthase mRNA. *J. Biol. Chem.* 271:27184.
- Haque, S. J., V. Flati, A. Deb, and R. G. Williams. 1995. Roles of protein-tyrosine phosphatases in Stat1 α -mediated cell signaling. *J. Biol. Chem.* 270:25709.
- Haque, S. J., Q. Wu, W. Kammer, K. Friedrich, and J. M. Smith. 1997. Receptor-associated constitutive protein tyrosine phosphatase activity controls the kinase function of JAK1. *Proc. Natl. Acad. Sci. USA* 94:8563.
- Ohmori, Y., S. Fukumoto, and T. A. Hamilton. 1995. Two structurally distinct κ B sequence motifs cooperatively control LPS-induced KC gene transcription in mouse macrophages. *J. Immunol.* 155:3593.
- Nicholson, S., M. G. Bonecini-Almeida, J. R. Lapa e Silva, C. Nathan, Q. W. Xie, R. Mumford, J. R. Weidner, J. Calayacay, J. Geng, N. Boechat, et al. 1996. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. *J. Exp. Med.* 183:2293.
- Meyer, J., N. Richter, and M. Hecker. 1997. High-performance liquid chromatographic determination of nitric oxide synthase-related arginine derivatives *in vitro* and *in vivo*. *Anal. Biochem.* 247:11.
- Laurent, M., M. Lepoivre, and J. P. Tenu. 1996. Kinetic modelling of the nitric oxide gradient generated *in vitro* by adherent cells expressing inducible nitric oxide synthase. *Biochem. J.* 314:109.
- Eiserich, J. P., M. Hristova, C. E. Cross, A. D. Jones, and B. A. Freeman. 1998. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. *Nature* 391:393.
- Kurz, S., and D. G. Harrison. 1997. Insulin and the arginine paradox. *J. Clin. Invest.* 99:369.
- Hecker, M., W. C. Sessa, H. J. Harris, E. E. Anggard, and J. R. Vane. 1990. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-

- derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. *Proc. Natl. Acad. Sci. USA* 87:8612.
29. Hattori, Y., E. B. Campbell, and S. S. Gross. 1994. Argininosuccinate synthetase mRNA and activity are induced by immunostimulants in vascular smooth muscle. *J. Biol. Chem.* 269:9405.
 30. Hammermann, R., J. Hirschmann, C. Hey, J. Mossner, G. Folkerts, F. P. Nijkamp, I. Wessler, and K. Racké. 1999. Cationic proteins inhibit L-arginine uptake in rat alveolar macrophages and tracheal epithelial cells. *Am. J. Respir. Cell Mol. Biol.* 21:155.
 31. Lundberg, J. O. N., E. Weitzberg, J. Rinder, A. Rudehill, O. Jansson, N. P. Wiklund, J. M. Lundberg, and K. Alving. 1996. Calcium-independent and steroid-resistant nitric oxide synthase activity in human paranasal sinus mucosa. *Eur. Respir. J.* 9:1344.
 32. Kamijo, R., H. Harada, T. Matsuyama, M. Bosland, J. Gerecitano, D. Shapiro, J. Le, S. I. Koh, T. Kimura, S. J. Green, et al. 1994. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. *Science* 263:1612.
 33. Geller, D. A., A. K. Nussler, M. D. Silvio, C. J. Lowenstein, R. A. Shapiro, S. Wang, R. L. Simmons, and T. R. Billiar. 1993. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. *Proc. Natl. Acad. Sci. USA* 90:522.
 34. Radomski, M.W., R. M. J. Palmer, and S. Moncada. 1990. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. *Proc. Natl. Acad. Sci. USA* 87:10043.
 35. Kunz, D., G. Walker, W. Eberhardt, and J. Pfeilschifter. 1996. Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expression in interleukin 1 β -stimulated mesangial cells: evidence for the involvement of transcriptional and posttranscriptional regulation. *Proc. Natl. Acad. Sci. USA* 93:255.
 36. Eissa, N. T., J. W. Yuan, C. M. Haggerty, E. K. Choo, C. D. Palmer, and J. Moss. 1998. Cloning and characterization of human inducible nitric oxide synthase splice variants: a domain, encoded by exons 8 and 9, is critical for dimerization. *Proc. Natl. Acad. Sci. USA* 95:7625.
 37. Marks-Konczalik, J., S. C. Chu, and J. Moss. 1998. Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor κ B-binding sites. *J. Biol. Chem.* 273:22201.
 38. Taylor, B. S., M. E. de Vera, R. W. Ganster, Q. Wang, R. A. Shapiro, S. M. Morris, T. R. Billiar, and D. A. Geller. 1998. Multiple NF- κ B enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. *J. Biol. Chem.* 273:15148.
 39. de Vera, M. E., R. A. Shapiro, A. K. Nussler, J. S. Mudgett, R. L. Simmons, S. M. Morris, and T. R. Billiar. 1996. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. *Proc. Natl. Acad. Sci. USA* 93:1054.
 40. Haque, S. J., and B. R. G. Williams. 1998. Signal transduction in the interferon system. *Semin. Oncol.* 25:14.
 41. Hill, C. S., and R. Treisman. 1995. Transcriptional regulation by extracellular signals: mechanisms and specificity. *Cell* 80:199.
 42. Malinski, T., Z. Taha, S. Grunfeld, S. Patton, M. Kapturczak, and P. Tomboulian. 1993. Diffusion of nitric oxide in the aorta wall monitored in situ by porphyrinic microsensors. *Biochem. Biophys. Res. Commun.* 193:1076.
 43. Wink, D. A., I. Hanbauer, M. B. Grisham, F. Laval, R. W. Nims, J. Laval, J. Cook, R. Pacelli, J. Liebmann, M. Krishna, et al. 1996. Chemical biology of nitric oxide: regulation and protective and toxic mechanisms. *Curr. Top. Cell. Regul.* 34:159.
 44. Gaston, B., S. Sears, J. Woods, J. Hunt, M. Ponaman, T. McMohan, and J. S. Stamler. et al. 1998. Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure. *351:1317*.
 45. Gaston, B., J. Reilly, J. M. Drazen, J. Fackler, P. Ramdev, D. Arnelle, M. E. Mullins, D. J. Sugarbaker, C. Chee, D. J. Singel, et al. 1993. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. *Proc. Natl. Acad. Sci. USA* 90:10957.
 46. Eiserich, J. P., A. G. Estevez, T. V. Bamberg, Y. Z. Ye, P. H. Chumley, J. S. Beckman, and B. A. Freeman. et al. 1999. Microtubule dysfunction by posttranslational nitrotyrosination of α -tubulin: a nitric oxide dependent mechanism of cellular injury. *Proc. Natl. Acad. Sci. USA* 96:6365.
 47. Baydoun, A. R., P. W. Emery, J. D. Pearson, and G. E. Mann. 1990. Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endothelial cells. *Biochem. Biophys. Res. Commun.* 173:940.
 48. Hart, L. A., V. L. Krishnan, I. M. Adcock, P. J. Barnes, and K. F. Chung. 1998. Activation and localization of transcription factor, nuclear factor- κ B, in asthma. *Am. J. Respir. Crit. Care Med.* 158:1585.
 49. Iyengar, F., D. J. Stuehr, and M. A. Marletta. 1987. Macrophage synthesis of nitrite, nitrate, and N-nitrosamines: precursors and role of the respiratory burst. *Proc. Natl. Acad. Sci. USA* 84:6369.
 50. McDonald, K. K., S. Zharikov, E. R. Block, and M. S. Kilberg. 1997. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox." *J. Biol. Chem.* 272:31213.
 51. Granger, D. L., J. B. Hibbs, J. R. Perfect, and D. T. Durack. 1990. Metabolic fate of L-arginine in relation to microbistatic capability of murine macrophages. *J. Clin. Invest.* 85:264.
 52. Kobzik, L., D. S. Bredt, C. J. Lowenstein, J. Drazen, B. Gaston, D. Sugarbaker, and J. S. Stamler. 1993. Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. *Am. J. Respir. Cell Mol. Biol.* 9:371.
 53. Look, D. C., M. R. Pelletier, and M. J. Holtzman. 1994. Selective interaction of a subset of interferon-g response element-binding proteins with the intercellular adhesion molecule-1 (ICAM-1) gene promoter controls the pattern of expression on epithelial cells. *Proc. Natl. Acad. Sci. USA* 269:8952.
 54. Sampath, D., M. Castro, D. C. Look, and M. J. Holtzman. 1999. Constitutive activation of an epithelial signal transducer and activation of transcription (STAT) pathway in asthma. *J. Clin. Invest.* 103:1353.
 55. Li, X. M., R. K. Chopra, T. Y. Chou, B. H. Schofield, M. Wills-Karp, and S. K. Huang. 1996. Mucosal IFN- γ gene transfer inhibits pulmonary allergic responses in mice. *J. Immunol.* 157:3216.
 56. Cembrzynska-Nowak, M., E. Szklarz, A. D. Inglot, and J. A. Teodorczyk-Injeyan. 1993. Elevated release of tumor necrosis factor- α and interferon- γ by bronchoalveolar leukocytes from patients with bronchial asthma. *Am. Rev. Respir. Dis.* 147:291.
 57. Hessel, E. M., A. J. M. Van Oosterhout, I. V. Ark, B. V. Esch, G. Hofman, H. V. Loveren, H. F. J. Savelkoul, and F. P. Nij Kamp. 1997. Development of airway hyperresponsiveness is dependent on interferon- γ and independent of eosinophil infiltration. *Am. J. Respir. Cell Mol. Biol.* 16:325.
 58. Hansen, G., G. Berry, R. H. DeKruyff, and D. T. Umetsu. 1998. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. *J. Clin. Invest.* 103:175.